Nilotinib (AMN107, Tasigna®, Novartis), a selective inhibitor of the tyrosine kinase activities of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem-cell growth factor receptor (c-KIT), is an encouraging therapeutic option for chronic myeloid leukemia (CML) patients with imatinib resistance or intolerance. This evidence concerns the gene PDGFRB and chronic myelogenous leukemia, BCR-ABL1 positive.